This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Start Date10 Feb 2025

Sponsor / Collaborator

The Children's Oncology Group Foundation, Inc.

NCT06175832 / Not yet recruitingPhase 4IIT

PPOS and CFA for Elective Freeze-all Ovarian Stimulation Cycles: a Prospective Cross-over Study

P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA/PPOS versus rFSH/GnRH ovarian stimulation cycles.

Start Date01 Nov 2024

Sponsor / Collaborator

Ghent University Hospital

NCT06487143 / Not yet recruitingPhase 4IIT

The Effects of the 3-month Formulation of Triptorelin (TP) Compared to the 1-month Formulation on the Efficacy, Glucose and Lipid Metabolism, and Bone Mineral Density(BMD) in Idiopathic Central Precocious Puberty(ICPP)

The primary objective of this study is to compare the efficacy of the 3-month formulation and 1-month formulation of triptorelin and to assess the short-term effects of the 3-month formulation of triptorelin on glucose and lipid metabolism, body composition, and bone density in Chinese ICPP patients.

Start Date01 Jul 2024

Sponsor / Collaborator

Sun Yat-Sen University

100 Clinical Results associated with Triptorelin Pamoate

100 Translational Medicine associated with Triptorelin Pamoate

100 Patents (Medical) associated with Triptorelin Pamoate

1,129

Literatures (Medical) associated with Triptorelin Pamoate

01 Dec 2024·UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer

Article

Author: Duh, Mei Sheng ; Ebrahimi, Ramin ; Morgans, Alicia K ; Preston, Mark A ; Dufour, Robert ; Hong, Agnes ; Hanson, Sarah ; Desai, Raj ; Bobbili, Priyanka ; Gandhi, Raj

BACKGROUND:

Intermittent androgen deprivation therapy (iADT) alleviates some side effects of continuous (c) ADT in patients with prostate cancer (PC), but its relative impact on ADT-associated comorbidities is uncertain. We assessed real-world use of iADT and cADT and associated risk of cardiovascular and endocrine/metabolic events in patients with nonmetastatic (nm) PC.

METHODS:

This retrospective longitudinal cohort study included patients with nmPC initiating systemic ADT with gonadotropin-releasing hormone agonists (goserelin, histrelin, leuprolide, and triptorelin) or antagonists (degarelix) in the US Surveillance, Epidemiology and End Results-Medicare database (2010-2017), who had ≥ 36 months of continuous insurance coverage, unless death occurred, and did not receive chemotherapy or next-generation hormonal therapies during follow-up (through 2019). Risk of major adverse cardiovascular events (MACE [myocardial infarction, stroke, cardiomyopathy/heart failure, pulmonary embolism, ischemic heart disease, all-cause mortality]) and endocrine/metabolic events (diabetes, hypercholesterolemia, bone fractures, and osteoporosis) were examined between cohorts. Inverse probability of treatment-weighted Cox regression models estimated adjusted hazard ratios (HRs) of the outcomes.

RESULTS:

Of 10,655 eligible patients, 2,095 (19.7%) received iADT and 8,560 (80.3%) cADT. Median follow-up was 43.9 and 48.4 months and median ADT duration (excluding iADT gaps) was 22.0 and 13.5 months for the iADT and cADT cohorts, respectively. Patients receiving cADT had a lower risk of MACE vs. iADT (HR 0.90; 95% confidence interval [CI] 0.83-0.96). No difference in risk of endocrine/metabolic events was observed (HR 0.97; 95% CI 0.92-1.03). Subgroup analysis found that the difference in MACE was maintained in patients with a history of cardiovascular disease (HR 0.90; 95% CI 0.83-0.98) and eliminated in patients without (HR 0.94; 95% CI 0.82-1.08).

CONCLUSIONS:

Patients with nmPC who received cADT had a lower risk of MACE and similar risk of endocrine/metabolic events vs. those who received iADT. Further research assessing both regimens is needed to inform treatment decisions.

01 Dec 2024·ADVANCES IN THERAPY

A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty

Article

Author: Huang, Frank ; Xu, Xu ; Shi, Xiaofeng ; Li, Guimei ; Wei, Haiyan ; Cabri, Patrick ; Cheng, Xinran ; Yu, Xiao ; Yang, Yu ; Zhou, Li ; Luo, Xiaoping ; Zhong, Yan ; Luo, Feihong ; Zhang, Yining ; Gong, Chunxiu ; Yao, Hui

INTRODUCTION:

This phase 3 study assessed the efficacy, safety, and pharmacokinetics of the 6-month prolonged release (PR) formulation in Chinese children with central precocious puberty (CPP).

METHODS:

In this open-label study (NCT05029622), Chinese children (girls < 9 years, boys < 10 years) received two doses of triptorelin pamoate 22.5 mg (day 1 and month 6). Primary endpoint was the proportion at month 6 with luteinizing hormone (LH) suppression (stimulated peak LH ≤ 5 IU/L after gonadotropin-releasing hormone stimulation). Secondary endpoints included safety assessments, hormone level changes, and clinical parameters from baseline.

RESULTS:

Overall, 66 children completed the study (93.9% girls; median age 8.0 [range 5-9] years). At month 6, all patients had LH suppression; this was maintained at month 12 in 98.5% of patients. Mean basal and peak LH and follicle-stimulating hormone levels were suppressed throughout follow-up. All patients at months 3 to 12 had sex hormone suppression to prepubertal levels. Stable or reduced breast development was seen for 98.4% and 93.5% of girls at month 6 and 12, respectively; all boys had regression or stable genital development until month 12. Compared with baseline (9.82 cm/year), mean growth velocity was 5.88 cm/year at month 6 and 5.17 cm/year at month 12. Mean bone age/chronological age ratio decreased from 1.27 at baseline to 1.23 and 1.21 at month 6 and 12, respectively. In girls, 64.5% showed decreased uterine length at month 6 and 12 versus baseline, while 75.0% of boys showed stable testicular volume versus baseline. Thirteen patients (19.7%) had 22 drug-related treatment emergent adverse events (TEAEs); no grade ≥ 3 TEAEs were reported.

CONCLUSION:

The efficacy and safety profile of triptorelin 6-month PR in Chinese children with CPP was consistent with data previously reported in non-Chinese children with CPP, supporting this as a viable treatment option for Chinese children with CPP.

TRIAL REGISTRATION:

Trial registration: ClinicalTrials.gov identifier, NCT05029622.

30 Oct 2024·International Journal of Fertility & Sterility

Potential Effects of Soy Isoflavones and Broccoli Extract on Oxidative Stress, Autophagy, and Apoptosis Gene Markers in Endometriosis.

Article

Author: Zal, Fatemeh ; Sabetian, Soudabeh ; Dara, Mahintaj ; Samare-Najaf, Mohammad ; Vakili, Sina ; Tanideh, Nader ; Siahbani, Sarah ; Namavar Jahromi, Bahia ; Khodabandeh, Zahra

BACKGROUND:

Endometriosis is an idiopathic gynecological condition affecting women with pelvic pain and infertility in reproductive ages. Due to preventive and therapeutic effects of soy isoflavones (SI) and broccoli extract (BE) on tumor angiogenesis, inflammation and oxidative stress and since endometriosis is accompanied by chronic inflammation, in this study, we aim to evaluate the potential role of these compounds on the pathological scores of endometriosis and also consider the expression level of the gene markers of autophagy, apoptosis, and oxidative stress in an endometriosis rat model.

MATERIALS AND METHODS:

In the present experimental study, 45 mature female Sprague- Dawley rats weighing 220 ± 20 g at the age of eight weeks with surgically induced endometriosis was divided into five groups and treated for six weeks with normal saline (control group), BE, SI, BE+SI by oral gavage, and also Diphereline intramuscularly. The histopathological scores of the endometrial implants (0, 1, 2, 3: no, poorly, moderately and well-preserved epithelial layers, respectively) and the mRNA expression level of Bcl-2, Bax, Caspase-3, Beclin-1, Lc3, and Sod within peritoneal tissue were compared among the groups.

RESULTS:

Pathologic scores of the implants in the Diphereline (1.2 ± 0.27) and BE+SI (1.2 ± 0.41) groups were declined significantly in comparison with the control group (2.08 ± 0.44) (P≤0.001). In the endometriotic structures, the mRNA expression levels of our target genes were improved significantly (P≤0.01) in comparison with the control group.

CONCLUSION:

The findings of the current study demonstrated that the simultaneous consumption of a certain amount of broccoli extract and SI can be considered as a promising therapeutic strategy for treatment of endometriosis.

News (Medical) associated with Triptorelin Pamoate

04 Dec 2024

·www.prnewswire.com

Foresee Pharmaceuticals Announces Completion of US$42.1 Million Financing

TAIPEI, Dec. 4, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announces that it has successfully completed an underwritten public offering of 18,000,000 shares of its common stock to the public at a price of NT$76 per share. The aggregate gross proceeds to Foresee from the offering were NT$1,368 million (or US$42.1 million at FX=32.5). The proceeds of the public offering will be used for general corporate purposes, including FP-014 (triptorelin), a ready-to-use long-acting injectable, administered either every three months or six months, in two Phase 3 clinical trials for advanced prostate cancer, respectively; FP-020 (linvemastat), an MMP-12 inhibitor, in two Phase 2 studies for both asthma and inflammatory bowel disease (IBD), and FP-045 (mirivadelgat), an ALDH2 activator, in a Phase 2 clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD). "We are pleased to announce the successful completion of the public offering. I would like to express my gratitude once again for shareholders' full support and trust in us." said Dr. Ben Chien, Founder and Chairman of Foresee. "This funding will enable us to accelerate our R&D progress and create more value for our shareholders." About Foresee Pharmaceuticals Co., Ltd. Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI® 42 mg or the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and was launched in the U.S. in April 2022. Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted, while the EU regulatory submission for the 3-month version of CAMCEVI is still under preparation. For the second indication of CAMCEVI 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study, is ongoing. Another indication of CAMCEVI 6-month LAI formulation, premenopausal breast cancer, the Phase 3 clinical trial in China is ongoing as well. Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, for which a Phase 1 study in healthy volunteers has been successfully completed, with development targeted in severe asthma, COPD and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the FuschiA Phase 1b/2 Fanconi Anemia study is ongoing, and the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning with targeted initiation in the first quarter of 2025. Building on the compelling biology of ALDH2, and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space. SOURCE Foresee Pharmaceuticals Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Phase 3Clinical ResultPhase 1Drug Approval

09 Sep 2024

·www.debiopharm.com

First Patients Dosed in Debiopharm’s Phase III Trial (LIBELULA) Investigating Debio 4326, A 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

Debiopharm’s expertise in extended-release formulations could lighten the burden of treatment for children with Central Precocious Puberty (CPP) and their families by reducing injection frequency to once a year Lausanne, Switzerland – September 9th, 2024 – Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the dosing of the first sentinel patients in its open-label, single-arm, multi-center Phase III study, NCT06129539 ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)’. Triptorelin is an established treatment for CPP as a 1-, 3- and 6-month formulation. This new phase III study evaluating the novel 12-month triptorelin formulation is being carried out in North and South America. In pursuit of developing safe, effective, and convenient treatment options for patients, Debiopharm, is applying its expertise in extended-release formulations to achieve the first yearly injectable Gonadotropin-Releasing Hormone agonist (GnRHa). Reducing treatment burden while preserving triptorelin’s well-known efficacy and safety are key elements that Debiopharm is eager to assess through this study. “It is always disheartening to see such young children burdened by the effects of central precocious puberty and the lifelong complications it may cause. We are thankful that treatments like triptorelin are already on the market, and that companies like Debiopharm continue to invest in lightening the patient care burden with formulations that reduce injection frequency.” expressed Prof. Fernando Cassorla, Principal Investigator, Pediatrics Department at the Hospital San Borja Arriarán in Santiago, Chile. “As patients are at the center of all we do, we recognize that convenience matters. Reducing injection frequency to once a year can lower the burden for CPP patients and their caretakers by reducing children’s stress and improving overall compliance. We are enthusiastic about the first patients enrolled in this phase III trial that can bring both medical and practical advancements.” expressed Bertrand Ducrey, CEO of Debiopharm. About Central Precocious Puberty Central precocious puberty (CPP) occurs at an unusually early age, before 8 years of age in girls and before 9 years of age in boys [1-2]. It is characterized by a premature development of secondary sexual characteristics (e.g. breasts for girls and enlarged testicles for boys), accelerated growth, and bone maturation leading to reduced adult height. CPP is triggered by the early release of the gonadotropin-releasing hormone in the brain and premature activation of the hypothalamic-pituitary-gonadal axis. This early activation can be due to specific genetic alterations, central nervous system lesions, and social stressors but frequently has no identified etiology [3]. The approximative prevalence of CPP is 1 in 5,000-10,000 among Caucasians, more frequent in girls than in boys globally [4]. Precocious puberty may be associated with psychosocial difficulties and carries potential negative implications for long-term health including increased risk of metabolic complications, such as type 2 diabetes, weight gain, obesity, cardiovascular disease, as well as depression, and even premature death [5-10]. Early puberty has also been associated with an increased risk of breast cancer in women. In men, it may increase the risk of prostate cancer [11-13]. Since the early 1980s, Gonadotropin-Releasing Hormone agonists (GnRHa) such as triptorelin have been the standard of care for the treatment of CPP [14-16]. Treatment aims to preserve adult height and prevent social and psychological difficulties and the various potential consequences on long-term health. Currently, there are several different extended-release GnRHa formulations ranging from monthly injections to subcutaneous implants for annual use [17]. While the latter may have a longer duration of action, it requires yearly surgical positioning. About Debio 4326 Debio 4326 is a unique injectable, biodegradable 12-month extended-release formulation of triptorelin designed to further reduce the frequency of injections and burden of administrations, particularly considering its intended use in a pediatric population. Based on favorable efficacy and safety data with the different triptorelin 1-, 3- and 6-month formulations, Debio 4326 aims to preserve efficacy while providing increased comfort, ensure long-term compliance, and reduce stress for children and their parents. Debiopharm’s commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit www.debiopharm.com We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews Sources [1] Latronico AC, et al. Lancet Diabetes Endocrinol. 2016;4(3):265–274. [PubMed: 26852255] [2] Sanctis V, et al. Acta biomedica: Atenei Parmensis. 2019 90 (3): 345-359. [3] Maione L, et al. Clin Endocrinol (Oxf). 2021 Oct;95(4):542-555. doi: 10.1111/cen.14475. Epub 2021 Apr 20. PMID: 33797780; PMCID: PMC8586890 [4] National Organization for Rare Disorders (NORD) 2022 [5] Day FR, et al. 2015. Sci Rep, 5: 11208. [6] Elks CE, et al. 2013. Diabetes Care, 36 (11): 3526-34. [7] Prentice P, and Viner RM. 2013. Int J Obes (Lond), 37 (8): 1036-43 [8] Ong KK, et al. 2012. J Clin Endocrinol Metab, 97 (8): 2844-52. [9] Hamlat EJ, et al. 2014. J Abnorm Child Psychol, 42 (4): 527-38. [10] Charalampopoulos D, et al. 2014. Am J Epidemiol, 180 (1): 29-40. [11] Day FR, et al. 2017. Nat Genet, 49 (6): 834-41. [12] Bonilla C, et al. 2016. BMC Med, 14: 66. [13] Bräuner EV, et al. 2020. JAMA Netw Open, 3 (10): e2015665 [14] Carel JC, et al. 2009. Pediatrics, 123 (4): e752-62. [15] Bertelloni S, et al. 2015. Horm Res Paediatr, 84 (6): 396-400. [16] Bangalore Krishna K, et al. 2019. Horm Res Paediatr, 91 (6): 357-72. [17] Aguirre RS, Eugster EA. Best Pract Res Clin Endocrinol Metab. 2018;32(4):343–354.

Phase 3Phase 2

09 Aug 2024

·www.prnewswire.com

Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products

TAIPEI, Aug. 9, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced several new developments related to its SIF long-acting injectable (LAI) technologies, namely the disclosure of its four novel and proprietary SIF LAI delivery systems: SIF-ADAGIOTM, SIF-LEGATOTM, SIF-DUOTM, and SIF-MEZZOTM. Continue Reading View PDF Building on the tremendous success of its first SIF-derived product CAMCEVI®, Foresee has been continuously developing and expanding its SIF technology platform as well as its industry dominance and leadership in the area of LAI's, from the technology, intellectual property and product development perspective. In view of the complexity of LAI's, requiring a remarkable depth of know-how, expertise, and experience, very few organizations have developed a LAI technology platform with the level of flexibility and adaptability that can be found in the SIF platform. In fact, Foresee has now developed four distinct SIF LAI delivery systems that will enable even greater flexibility and allow to continue to push the boundaries of innovation in complex LAI products. Foresee will be disclosing more information on these new SIF delivery systems over the upcoming months. Below is a summary: Foresee's commercial product CAMCEVI® was developed using its SIF-ADAGIOTM delivery system, based on biodegradable polymers. Foresee is also applying its SIF-ADAGIOTM system to other products in the portfolio, namely FP-014, its best-in-class ready-to-use, subcutaneous, 3 and 6-month triptorelin LAI. The SIF-LEGATOTM system is a novel combination lipid-based system that has the unique advantage of permitting very high drug loading, making it highly adaptable to various drug substances and product profiles. This SIF LAI delivery system is currently being employed for the development of several early neurology products in our portfolio. SIF-DUOTM is a solution-based system which Foresee is using for the development of some of its early psychiatry LAI programs that benefit from this unique delivery system, while our SIF-MEZZOTM delivery system remains in development and optimization phase. "We are pleased to announce these recent developments in our SIF LAI technologies," said Dr. Ben Chien, Foresee's Chairman and CEO. "While we remain very committed to the advancement of our product portfolio across both SIF and NCE programs, we continue to make significant strides in advancing the technology and intellectual property foundations on which we have built our company. A key part of our mission is to remain a leader in complex LAI products and technologies." "We are very enthusiastic about the promise of these emerging SIF delivery systems. We have proven the value of our technology and expertise through the application of our SIF-ADAGIOTM system to CAMCEVI®, a best-in-class product growing successfully in the market, now we are ready to embark in the second phase of our mission by demonstrating the commercial potential of the new delivery systems," said Dr. Yuhua Li, Foresee's Chief Technology Officer. About Foresee Pharmaceuticals Co., Ltd. Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused in two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI® 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan and Israel and launched in the U.S. in April 2022. Additionally, U.S. and EU regulatory submissions are under preparation for CAMCEVI® 21 mg. For the second indication of CAMCEVI® 42 mg, central precocious puberty (CPP), the Casppian Phase 3 clinical study, has been initiated. FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study has been completed with positive outcomes, with future development in rare immune-fibrotic diseases. FP-020, a follow-on oral MMP-12 inhibitor currently in Phase 1, with development targeted in severe asthma, COPD and IBD. FP-045 is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the FuschiA Phase 1b/2 Fanconi Anemia study is currently being initiated, and the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is in planning with targeted initiation in the fourth quarter of 2024. Building on the compelling biology of ALDH2, and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space. SOURCE Foresee Pharmaceuticals Co., Ltd.

Phase 2Phase 1Phase 3

100 Deals associated with Triptorelin Pamoate

External Link

KEGG	Wiki	ATC	Drug Bank
D06248	Triptorelin Pamoate	L02AE04	DB06825

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Puberty, Precocious	US	Azurity Pharmaceuticals, Inc.	29 Jun 2017
Hormone-dependent prostate cancer	AU	Ipsen Pty Ltd.	28 Aug 2006
Prostatic Cancer	KR	Ferring Pharmaceuticals Korea Co., Ltd.	04 Nov 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Familial Testotoxicosis	NDA/BLA	CN	Ipsen SA	22 Jan 2007
Endometriosis	Phase 3	CN	Ipsen SA	28 Jul 2017
Metastatic Prostate Carcinoma	Phase 3	BG	Ipsen SA	01 Jan 2013
Metastatic Prostate Carcinoma	Phase 3	PL	Ipsen SA	01 Jan 2013
Advanced Prostate Carcinoma	Phase 3	BE	Ipsen SA	01 Nov 2009
Advanced Prostate Carcinoma	Phase 3	DK	Ipsen SA	01 Nov 2009
Advanced Prostate Carcinoma	Phase 3	FR	Ipsen SA	01 Nov 2009
Advanced Prostate Carcinoma	Phase 3	IT	Ipsen SA	01 Nov 2009
Advanced Prostate Carcinoma	Phase 3	LV	Ipsen SA	01 Nov 2009
Advanced Prostate Carcinoma	Phase 3	LT	Ipsen SA	01 Nov 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05029622 (Pubmed \| Adv Ther)	Phase 3	Puberty, Precocious	66	Triptorelin pamoate 22.5 mg	wcnvcypuyj(xusxxdises) = Thirteen patients (19.7%) had 22 drug-related treatment emergent adverse events (TEAEs); no grade ≥ 3 TEAEs were reported rcpumwjgyb (gljqklpwtz ) View more	Positive	01 Dec 2024
NCT04736602 (CTgov)	Phase 3	Puberty, Precocious	32	triptorelin pamoate	yurqjlqpch(pqoecevdmx) = tolcecwqag asuqmbpkal (vjbwhwijox, yrvfujtxyv - klrheztmin) View more	-	01 Aug 2024
NCT05029622 (CTgov)	Phase 3	Puberty, Precocious	66	triptorelin pamoate	ebrqjinxtr(utzjwvxuer) = drsyosutaj jnqhqmsxut (eypztmyopv, clmcaxzwzg - nngvhtxmtz) View more	-	28 May 2024
NCT04736602 (Pubmed \| Adv Ther)	Phase 3	Puberty, Precocious luteinizing hormone (LH) \| follicle-stimulating hormone	32	Triptorelin pamoate 15 mg	nflhskbvho(jbeadvyiya) = apzamzoivc febimngjmw (kfqkxrdjfe ) View more	Positive	01 Oct 2023
ESPE2023	Not Applicable	Puberty, Precocious	8	Triptorelin	kugrwnjaly(syvobqcqve) = srajhxdplc acffjkcxfn (bsqrjnbbis ) View more	-	21 Sep 2023
ESPE2022	Not Applicable	Puberty, Precocious luteinizing hormone (LH) \| follicle stimulation hormone (FSH)	656	Triptorelin	lyxfvzudxg(hdycunmbji) = lrusncksrq ypfebfudda (twkzcjxxwq )	-	15 Sep 2022
ESPE2022	Not Applicable		656	Subcutaneous Triptorelin stimulation test	lyxfvzudxg(hdycunmbji) = sxgywrnvqh ypfebfudda (twkzcjxxwq )	-	15 Sep 2022
ESPE2022	Not Applicable	Puberty, Precocious	42	Triptorelin 6-month formulation	runhepwhjq(xpnrcahhdy) = No adverse effect was observed during treatment lcocqfrzad (zegqljqetc ) View more	-	15 Sep 2022
ESPE2022	Not Applicable	Puberty, Precocious	186	Triptorelin	zmllboacjf(lchnhrfena) = enuvbzbptc otxeviqjhw (tuxizwqwsg )	-	15 Sep 2022
NCT04537078 (CTgov)	Phase 3	Infertility, Female	90	Combined Oral Contraceptive+Decapeptyl+Cyclo-Progynova+progesterone+Gonadotropin+Duphaston (the Progestin Primed Double Stimulation Group)	ylqfuuygwt(qxwjxvhsdn) = clzsivsceb unnnxzukhc (ecytqppvdy, qkpvapxpjz - nuvusjibcr) View more	-	17 Feb 2022
NCT04537078 (CTgov)	Phase 3	Infertility, Female	90	Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone+Chorionic Gonadotropin+Gonadotropin (the Flexible GnRh Antagonist)	hcnqsabmmj(ajpqkgxnka) = yyerhzbylx cqrzeienrw (rdgaqhsxdg, fnqzxtmzmz - btlvwbnjzo) View more	-	17 Feb 2022
NCT03232281 (CTgov)	Phase 3	Endometriosis	300	Triptorelin Pamoate PR 3-month (Triptorelin Pamoate PR 3-month)	gumsacctgp(levututnii) = iivqgubcvz rggstdhaqm (jzuvzesvra, jchbnxvein - cunfehaxub) View more	-	14 Oct 2021
NCT03232281 (CTgov)	Phase 3	Endometriosis	300	Triptorelin Acetate PR 1-month (Triptorelin Acetate PR 1-month)	gumsacctgp(levututnii) = gjmklpwvai rggstdhaqm (jzuvzesvra, ktdxcmcmvc - aongdkqtcn) View more	-	14 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis